UnitedHealth Stock Down 15.9% in 3 Months: Should You Hold or Fold?

Shares of the major healthcare plan provider UnitedHealth Group Incorporated UNH have plunged 15.9% in the past three-month period, outperforming the industry’s decline of 17.5%. However, this decline prompts investors to question whether to maintain their positions or sell their shares.Peers such as Elevance Health, Inc. ELV and Centene Corporation CNC also experienced declines of 31.9% and 23.6%, respectively, in the past three months. The S&P 500 Index rose 6.5% in the same time frame.UNH’s 3-Month Price Performance ComparisonImage Source: Zacks Investment ResearchMounting public criticism of the insurance industry, reignited by the recent killing of the UNH CEO Brian Thompson and online backlash, has put insurers under intense scrutiny. Legislative pressures, such as the bipartisan bill targeting pharmacy benefit managers and conflicts of interest in the healthcare system, have further weighed on investor confidence. Additionally, broader concerns over rising healthcare costs, regulatory uncertainties, and the potential impact of reforms on insurers' profit margins have exacerbated the downward pressure on the stock.From a valuation perspective, UnitedHealth is trading at a premium compared to the industry average. The company's shares are currently priced at a forward 12-month price/earnings ratio of 16.33, higher than its five-year median of 19.20 and the industry average of 13.75.Image Source: Zacks Investment ResearchUnitedHealth’s robust fundamentals and growth prospects cannot be ignored. Let's have a look at its prospects and growth drivers.UNH’s 2025 GuidanceUNH has provided its 2025 financial guidance, projecting revenues of $450-$455 billion. Optum and UnitedHealthcare sales are estimated to be in the range of $277 billion-$280 billion and $337 billion-$340 billion, respectively.Adjusted earnings per share is forecasted to be $29.50-$30 compared with $27.50-$27.75 in 2024.  It expects operating cash flows of $32-$33 billion, with capital expenditures around $4 billion. Additionally, the UnitedHealthcare segment is projected to serve 50.97-51.32 million members by 2025.Growth DriversUnitedHealth’s growth is driven by several factors, including rising commercial membership in the domestic market, expansion in Optum Health's value-based care and new client acquisitions for Optum Rx. Strong membership trends in its Commercial segment reflect its competitive positioning and service diversification, which have supported steady momentum.The company’s financial flexibility is evident in its consistent cash flow, enabling initiatives to boost shareholder value. Operating cash flow jumped 17.3% and 10.9% in 2022 and 2023, respectively. Despite the cyber-attack on its Change Healthcare business in the first quarter, it generated operating cash flows of $21.8 billion in the first nine months of 2024.In June 2024, UnitedHealth raised its quarterly dividend by 12% and returned $9.6 billion to shareholders through buybacks and dividends in the first nine months of 2024. With a dividend yield of 1.73%, which exceeds the industry average of 1.64%, UnitedHealth has a history of consistent dividend increases since 2010.Healthcare spending in the United States is increasing, driven by rising disease prevalence. UnitedHealth is well-positioned to benefit from this trend, leveraging its diverse offerings to offset margin pressures from slower private Medicare rate growth.UNH’s Estimate RevisionsUNH’s 2024 and 2025 earnings estimates have witnessed downward adjustments in the past 60 days. Rising medical costs, partly due to the lingering effects of the pandemic, aggressive billing by hospitals and states reducing Medicaid coverage may have resulted in downward adjustments. The company anticipates a medical care ratio of 86.5% (±50 basis points) for 2025, higher than the 2024 expected figure of nearly 84.8%.However, UNH’s stock still holds promise considering its strong financial fundamentals and segmental growth prospects, helping build resilience against these short-term challenges.Image Source: Zacks Investment ResearchConclusionThere is no doubt that UNH is facing challenges, firm-specific and industry-specific, leading to a decline in its stock price and a downward revision in its 2024 and 2025 earnings estimates. Moreover, UNH's valuation premium compared to its industry peers raises a concern.However, UnitedHealth's diversified revenue streams, driven by Optum and UnitedHealthcare, robust cash flow generation, consistent dividend growth, and shareholder-friendly initiatives provide a solid foundation for long-term growth. Given these aspects, retaining this Zacks Rank #3 (Hold) stock appears prudent. Meanwhile, new investors might consider waiting for a more attractive entry point while keeping an eye on its cost-curbing efforts. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Free Today: Profiting from The Future’s Brightest Energy SourceThe demand for electricity is growing exponentially. At the same time, we’re working to reduce our dependence on fossil fuels like oil and natural gas. Nuclear energy is an ideal replacement.Leaders from the US and 21 other countries recently committed to TRIPLING the world’s nuclear energy capacities. This aggressive transition could mean tremendous profits for nuclear-related stocks – and investors who get in on the action early enough.Our urgent report, Atomic Opportunity: Nuclear Energy's Comeback, explores the key players and technologies driving this opportunity, including 3 standout stocks poised to benefit the most.Download Atomic Opportunity: Nuclear Energy's Comeback free today.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Centene Corporation (CNC): Free Stock Analysis Report Elevance Health, Inc. (ELV): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks